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Spontaneous CD4+ and CD8+ T-cell responses directed
against cancer testis antigens are present in the
peripheral blood of testicular cancer patients
Hayden Pearce1 , Paul Hutton2, Shalini Chaudhri2, Emilio Porfiri2,3,
Prashant Patel2,3, Richard Viney2 and Paul Moss1,2
1 Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences,
University of Birmingham, Birmingham, UK
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Cancer/testis antigen (CTAg) expression is restricted to spermatogenic cells in an
immune-privileged site within the testis. However, these proteins are expressed aber-
rantly by malignant cells and T-cell responses against CTAgs develop in many cancer
patients. We investigated the prevalence, magnitude and phenotype of CTAg-specific
T cells in the blood of patients with testicular germ cell tumors (TGCTs). CD8+ and CD4+
T-cell responses against MAGE-A family antigens were present in 44% (20/45) of patients’
samples assayed by ex vivo IFN-γ ELISPOT. The presence of MAGE-specific CD8+ T cells
was further determined following short-term in vitro expansion through the use of pMHC-
I multimers containing known immunogenic peptides. Longitudinal analysis revealed
that the frequency of MAGE-specific T cells decreased by 89% following orchidectomy
suggesting that persistence of tumor antigen is required to sustain CTAg-specific T-cell
immunity. Notably, this decrease correlated with a decline in the global effector/memory
T-cell pool following treatment. Spontaneous T-cell immunity against CTAg proteins
therefore develops in many patients with testicular cancer and may play an important
role in the excellent clinical outcome of patients with this tumor subtype.
Keywords: Cancer testis antigens  MAGE  T cells  Testicular cancer  Tumor immunology
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Testicular cancer is the most common tumor among young men
of 20–34 years of age and is increasing in incidence [1]. Testic-
ular germ cell tumors (TGCTs) account for the majority of tes-
ticular cancers and consist predominantly of classical seminomas
and nonseminomatous germ cell testicular tumors (NSGCTTs).
Correspondence: Prof. Paul Moss
e-mail: P.Moss@bham.ac.uk
Seminomas are morphologically homogeneous whilst NSGCTTs
are more heterogeneous and can be composed of multiple compo-
nents including embryonic carcinoma, choriocarcinoma cells and
teratoma [2]. In addition, some testicular germ cell tumors can
contain both seminoma and NSGCTT elements and these are clas-
sified as mixed germ cell tumors (mGCTs).
All post-pubertal TGCTs are thought to originate from a pre-
invasive lesion termed germ cell neoplasia in situ (GCNIS) [3].
Genome-wide expression profiling studies suggest that GCNIS cells
are derived from pluripotent gonocytes that have survived within
the post-natal testis [4, 5] and subsequent post-pubertal signals
C© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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from surrounding somatic cells may initiate the development of
an invasive tumor.
Cancer/testis antigens (CTAg) are proteins that are expressed
in germ cells but are usually silenced in somatic cells [6]. They
include the melanoma-associated antigen (MAGE) family and NY-
ESO-1 antigen which are attractive candidates for cancer vaccine
trials and adoptive cellular immunotherapy [7–9]. Importantly,
CTAg expression is observed in many tumor subtypes and incom-
plete clonal deletion of CTAg reactive thymocytes in the thymus
can lead to the development of CTAg-specific T-cell responses
[10–12].
Study of CTAg expression in testicular cancer has revealed
that MAGE-A family proteins are expressed frequently in classical
seminoma and seminomatous elements of mGCTs but are gener-
ally absent in GCNIS [13–20]. Conversely NY-ESO-1 expression is
limited to pre-invasive GCNIS [21] and is usually negative in both
seminoma and NSGCTT [16–18] indicating a pattern of downreg-
ulation during transition to carcinoma.
As testicular cancer is itself a germ cell tumor we investigated if
cellular immunity against CTAg proteins develops in patients with
testicular tumors. We find that strong CD8+ and CD4+ CTAg-
specific T-cell responses are indeed found in many patients and
that the global memory T-cell pool is also substantially increased
at diagnosis. The magnitude of CTAg-specific responses decreases
substantially after treatment and coincides with a reduction in
the T-cell memory pool. These data indicate that natural CTAg-
specific immunity is established in many patients with testicular
cancer and comprises a population of short-lived effector T cells
that persist poorly in the absence of antigen.
Results
Spontaneous T-cell responses against MAGE-A pro-
teins develop in many patients with testicular cancer
Forty-five patients with a diagnosis of testicular cancer were
recruited prior to orchidectomy or within 2 weeks of the operation.
PBMCs were stimulated with overlapping peptide pools derived
from CTAg proteins prior to analysis using IFN-γ ELISPOT assay.
T-cell responses were determined against peptide pools rep-
resenting MAGE-A1, MAGE-A3, MAGE-A4 and NY-ESO-1 and
were examined in all patients as well as 17 age-matched male
donors.
T-cell responses against MAGE proteins were observed in
many patients with testicular cancer. A representative ELISPOT
is shown in Fig. 1A. Specifically, T-cell responses to MAGE-A1
were detected in 17% (1/6) and 31% (9/29) of patients with
mixed germ cell tumors (mGCT) and seminoma respectively but
were absent in patients with non-seminomatous germ cell tes-
ticular tumors (NSGCTT) (Fig. 1B). MAGE-A3-specific responses
were detected in patients across all testicular tumor types
(Fig. 1C) with 31% (9/29) of seminoma, 50% (3/6) of mGCT
and 30% (3/10) of NSGCTT patients demonstrating an immune
response to this protein. MAGE-A4 responses were detected in
Figure 1. Enumeration of CTAg-specific T cells in testicular cancer
patients and healthy male donors. (A) Representative IFN-γ ELISPOTs
from a healthy male donor and a seminoma patient are shown. PBMCs
were stimulated with overlapping peptides spanning the full length
of the CTAg protein indicated. Each spot represents a single antigen-
specific IFN-γ secreting cell. Cells stimulated with DMSO alone served
as a negative control and a CEFT peptide pool was used as a positive
control. Computational analysis was used to count the spots in each
well. (B-F) Scatter dot plots show the frequency of (B) MAGE-A1, (C)
MAGE-A3, (D) MAGE-A4, (E) NY-ESO-1, and (F) CEFT-specific T cells in
healthy donors (n= 17) and patients with NSGCTT (n= 10), mGCT (n= 6)
and seminoma (n = 29). Each point represents the mean adjusted value
of 2 replicates for each individual patient and is expressed as the fre-
quency of CTAg-specific T cells /106 PBMCs. Dashed lines represent the
threshold for a positive response. (G) An overview of MAGE-A-specific
responses in TGCT patients by tumor type, showing the number of
patients exhibiting a positive response to 1, 2, or all 3 MAGE-A anti-
gens. Data shown were generated from the indicated number of donor
samples for each group.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 2. Effector function of MAGE-A-specific CD4+ and CD8+ T cells
stimulated with overlapping 15mer peptides. IFN-γ and TNF-α pro-
duction was assessed on both CD4+ and CD8+ T cells by intracellular
cytokine staining following restimulation with overlapping peptides in
a cohort of patients demonstrating a positive IFN-γ ELISPOT (n = 10). (A)
A representative flow cytometry density plot demonstrating the gating
strategy used to determine the subset of IFN-γ+TNF-α−, IFN-γ−TNF-α+
and IFN-γ+TNF-α+ T cells following pepmix stimulation is shown. (B)
The mean proportion of CD4+ and CD8+ T cells within each cytokine
subset was determined and is represented as a percentage of the total
CD4+ or CD8+ T-cell pool. Error bars represent SEM. (C) The correlation
between the proportion of cytokine-secreting CD4+ T cells and CD8+
T cells. Each symbol represents an individual patient and spearman’s
rank correlation coefficient (r) and significance (p) are reported. (D) The
proportion of CD107a-expressing CD8+ T cells within subsets of IFN-
γ+TNF-α+ and IFN-γ−TNF-α+ cells in response to peptide stimulation.
All data excluding (A) are pooled from 10 independent experiments.
Data shown as mean + SEM. Data analyzed by Mann–Whitney test,
**p < 0.01.
28% (8/29) of seminoma and 33% (2/6) of mGCT patients
(Fig. 1D), but were not identified in patients with NSGCTT. Inter-
estingly, NY-ESO-1-specific T-cell responses were undetectable in
all TGCT patients examined, irrespective of the tumor subtype
(Fig. 1E). The majority of patients and healthy donors responded
to the CEFT positive control (Fig. 1F). Overall, CTAg-specific
T-cell responses were detectable in 44% (20/45) of patients prior
to adjuvant therapy.
Further analysis revealed that a substantial proportion of
patients with seminoma and mGCT exhibited a T-cell immune
response against multiple MAGE-A family proteins (Fig. 1G). In
particular, of those exhibiting at least one response, 50% (7/14)
of patients with seminoma and 66% (2/3) of patients with mGCT
had responses to at least 2 of the 3 MAGE-A family antigens that
were examined. In contrast, NSGCTT patients generated responses
against only the MAGE-A3 protein. Interestingly, analysis of the
immune response in relation to clinical parameters revealed that
all NSGCTT patients with a MAGE-A3 directed immune response
had evidence of metastatic disease outside the testis. There was no
association between the frequency or magnitude of CTAg-specific
responses and tumor stage in patients with seminoma or mGCT
(data not shown).
MAGE-specific T cells comprise both CD4+ and CD8+
T cells and demonstrate a Th1 cytotoxic phenotype
In order to further characterize the CTAg-specific immune
response we next went on to define the T-cell subtype and effector
function in a group of patients with an established MAGE-specific
response (n = 10). PBMCs were stimulated with overlapping
peptides in short-term cultures and then intracellular cytokine
staining was used to examine IFN-γ and TNF-α production
(Fig. 2A). As expected given their previous identification through
IFN-γ ELISPOT, all patients demonstrated intracellular IFN-γ pro-
duction following peptide stimulation (data not shown). How-
ever, it was noteworthy that all patients also exhibited a high
frequency of MAGE-specific cells which produced TNF-α but not
IFN-γ and this IFN-γ−TNF-α+ phenotype was more pronounced
within the CD8+ T-cell compartment (Fig. 2B). The frequency of
MAGE-specific CD8+ T cells was 6-fold greater thanMAGE-specific
CD4+ T cells, yet a strong positive relationship within individual
donors was observed (r = 0.7697, p = 0.0156) (Fig. 2C) sug-
gesting the development of a coordinated CD4+ and CD8+ T-cell
response against such antigens.
Finally, we determined the cytotoxic capacity of CD8+ T cells
using CD107a surface mobilization as a marker of degranulation,
and analyzed this in relation to the cytokine secretion profile.
Importantly, although the majority of IFN-γ+TNF-α+ and IFN-
γ−TNF-α+ CD8+ T cells demonstrated surface mobilization of
Table 1. Immunodominant peptides used in dextramer assays
Protein HLA restriction HLA frequency (%) Peptide sequence Position
MAGE-A1 A2 42.6 KVLEYVIKV 278-286
B7 21.4 RVRFFFPSL 289-298
MAGE-A3 A1 29.1 EVDPIGHLY 168-176
A2 42.6 KVAELVHFL 112-120
MAGE-A4 A2 42.6 GVYDGREHTV 230-239
NY-ESO-1/LAGE-1 A2 42.6 MLMAQEALAFL 1 -11 (ORF2)
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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CD107a in response to peptide stimulation (mean: 97.5% vs.
85.3%) (Fig. 2D), nearly 15% of the latter subset failed to undergo
degranulation (p = 0.0054).
MAGE-specific CD8+ T cells can be identified through
staining with immunodominant pMHC-I multimers
Following identification of MAGE-specific CD8+ T cells through
cytokine production we next investigated if CTAg-specific T cells
could be identified through the use of staining with HLA-
peptide dextramers containing immunodominant peptides from
MAGE-A1, MAGE-A3, MAGE-A4 and/or NY-ESO-1/LAGE-1
(Table 1). Freshly isolated PBMCs were expanded with peptide
for 10 days prior to dextramer staining (Fig. 3A) and a positive
response was reported when the frequency of MAGE-specific
T cells was greater than 0.05% of the total CD8+ T-cell pool
(1 in 2000). MAGE-specific responses were detected in 36%
(8/22) of patients (Fig. 3B). MAGE-A1 (RVRF)-specific T-cell
responses were detected in 9% (2/22) of patients and almost a
third (32%) of patients had detectable MAGE-A3-specific T cells
(EVDP and/or KVAE). Importantly, whereas both patients who
demonstrated MAGE-A1 (RVRF)-specific responses had a diag-
nosis of seminoma, MAGE-A3 responses (EVDP and KVAE) were
detected in patients across all tumor subtypes (data not shown).
MAGE-A4 (GVYD) and NY-ESO-1/LAGE1 (MLMA)-specific T-cell
responses were not detected in this patient cohort. These results
confirm that CD8+ T-cell responses against a range of MAGE
proteins are present in patients with testicular cancer and that
these can be identified within the peripheral circulation through
the use of pMHC-I multimers.
MAGE-specific CD8+ T-cell clones display cytotoxic
activity against tumor cells
In order to investigate the avidity and function of CTAg-specific
T cells in patients with testicular cancer we next went on to gener-
ate a primary CTAg-specific T-cell clone from a patient with semi-
noma. A CD8+ T-cell clone specific for the EVDP peptide derived
fromMAGE-A3 and restricted byHLA-A1was isolated fromperiph-
eral blood taken at disease presentation (Fig. 3C, inset). Interest-
ingly, the clone exhibited a relatively low avidity for peptide with
50% maximal IFN-γ release (EC50) at a peptide concentration
of 4.58 × 10−7 M (Fig. 3C). Despite this the CD8+ clone demon-
strated strong and specific recognition of both peptide-pulsed LCLs
and the HT-29 cell line, indicating the ability to recognize tumor
cells which express endogenous CTAg protein (Fig. 3D). Finally,
the cytotoxic potential of the clone was examined through the
use of the CD107a mobilization assay. T cells were co-cultured
with either EVDP peptide-loaded LCL or HT-29 cells and expres-
sion of CD107a was then examined on effector cells. CD107a
expression was observed in both cases, indicating both that the
T-cell clone has cytotoxic capacity and that this can be induced
following endogenous antigen presentation of the MAGE protein
(Fig. 3E and F).
The frequency and magnitude of the CTAg-specific
T-cell response decrease markedly after treatment
We next went on to investigate the profile of CTAg-specific
immune responses during and after chemotherapy. Blood samples
were obtained at several time points from a cohort of seminoma
patients in whom we had detected a positive CTAg-specific T-cell
response prior to treatment. The frequency of MAGE-specific
T cells was assessed at least 3 months after completion of initial
treatment and compared to that prior to adjuvant therapy (Fig.
4A). Interestingly, the MAGE-specific immune response remained
detectable in only 22% of cases (4/18) at the later timepoint.
We next investigated the temporal kinetics of CTAg-specific
immunity to individual MAGE proteins within the observed period
of decline during follow up. Interestingly, a progressive decrease
in the frequency of antigen-specific T cells against each MAGE
protein was observed (Fig. 4B). Specifically, the magnitude of
the MAGE-specific T-cell response fell by 89% overall during
follow-up compared to pre-treatment values (median: 29.6 vs.
273, p = 0.0002). Importantly, we also studied if MAGE-specific
T-cell responses were induced following adjuvant treatment in
any patients in whom they had not been present at diagnosis
but no such responses were observed (data not shown) suggest-
ing that chemotherapy does not induce CTAg-directed anti-tumor
immunity.
Testicular cancer patients have a marked expansion
in the T-cell memory pool at disease presentation
In order to explore potential mechanisms that might underlie the
marked attrition of MAGE-specific T cells after treatment we went
on to investigate the composition of the peripheral T-cell memory
pool in patients both at diagnosis and following treatment. These
values were then compared to the proportions of memory cells in
age and gender matched healthy controls. The pattern of CD45RA
and CCR7 expression was used to define the proportion of naive
(CD45RA+CCR7+, TNaive), central memory (CD45RA−CCR7+,
TCM), CD45RA− effector/memory (CD45RA−CCR7−, TEM) and
CD45RA+ revertant effector (CD45RA+CCR7−, TEMRA) cells
within the CD4+ and CD8+ populations of healthy donors and
TGCT patients (Fig. 5A).
Interestingly, patients with testicular cancer were shown to
have a markedly increased proportion of T cells within the
memory pool and a significant reduction in the proportion of
na¨ıve cells. Specifically, within healthy donors the proportion of
CD45RA+CCR7+ TNaive cells represented 56% and 51% within
the CD4+ and CD8+ repertoires respectively. These values were
reduced by 25–40% to levels of 38 and 30% within the patient
group (p = 0.003 and p = 0.0008, respectively) (Fig. 5B). In con-
trast, the proportion of CD4+ TEM cells was increased from 23%
within healthy donors to 32% within TGCT patients (p = 0.0028).
CD8+ TEM cells were also increased by around 35% from val-
ues of 32% within healthy donors to 45% within the patient
group (p = 0.0284). Furthermore, the CD8+ TEMRA population
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 3. Detection and functional characterization of CD8+ T cells specific to immunodominant MAGE-A family epitopes in TGCT patients.
PBMCs from patients were stimulated with appropriate CTAg peptide in vitro for 10 days followed by staining with matched pMHC-I dextramer.
(A) Representative flow cytometry contour plots of KVAE (top), RVRF, (middle) and EVDP (bottom)–specific CD8+ T cells in TGCT patients prior
to chemotherapy are shown. (B) The frequency of CTAg-specific T cells represented as a percentage of the total CD8+ T-cell pool (n = 22). The
CTAg peptides within each pMHC-I dextramer are represented on the x-axis. The dashed line represents the threshold for a positive response.
# represents points from the same patient with a simultaneous MAGE-A1 and MAGE-A3 response. $ represents points from the same patient
who displayed responses to two different MAGE-A3 epitopes. (C) A MAGE-A3EVDP -specific CD8+ T-cell clone was generated from a seminoma
patient (inset), and its avidity for EVDP peptide was determined by peptide titration analysis. The avidity of the TCR was defined as the peptide
concentration required to induce half maximal IFN-γ release in an ELISA assay (dashed line: EC50). Data shown are of a single T-cell clone assayed
in triplicate. (D) EVDP-specific T cells were co-cultured with target cells and response wasmeasured using IFN-γ production by ELISA. EVDP-specific
T cells were co-cultured with EVDP loaded LCLs or MAGE-A3 expressing HT-29 cell line. Spontaneous IFN-γ production (open bars) was assessed by
culture of T cells alone, LCL alone, and HT-29 alone. Data shown are themean IFN-γ release of a single T-cell clone assayed in triplicate. LCL pulsed
with irrelevant peptide (KVAE) was also used to verify specificity of the clone. (E) The cytotoxic potential of a single EVDP-specific T-cell clone
was assessed in a degranulation assay using CD107a mobilization. Flow cytometry histograms show the proportion of T cells expressing CD107a
following stimulation with LCL pulsed with irrelevant peptide (KVAE) and test peptide (EVDP). (F) The induction of surface CD107a expression
was determined following co-culture with EVDP pulsed LCL and HT-29 cell line at an E:T ratio of 1:1, along with appropriate controls. CD107a
expression was represented as a percentage of total EVDP-specific T cells.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 4. Longitudinal analysis of the global CTAg-specific T-cell
response in patients with testicular cancer. (A) The frequency of MAGE-
A-specific T cells was measured by IFN-γ ELISPOT before (Pre) and after
the completion of adjuvant therapy (Post; 6 months) for a cohort
of seminoma patients in whom a positive response to MAGE-A1, -
A3, and/or -A4 had been detected prior to treatment, and where a
post-treatment sample was available. A total of 18 MAGE-A responses
from 10 patients were assayed in duplicate. (B) The percent reduction
of MAGE-specific T cells at two timepoints (Early, <3 months; Late,
6 months) after treatment, relative to the pre-treatment (Pre) fre-
quency. Data analyzed by Wilcoxon matched-pairs signed-rank test,
***p < 0.001.
was also increased in the patient group compared to the healthy
cohort (p = 0.0354). These data suggest that tumor development
is associated with the generation of large numbers of antigen-
experienced T cells that inflate the peripheral blood memory T-cell
pool.
Treatment of testicular cancer leads to a reduction in
the peripheral blood memory T-cell pool
Given our observation that patients with TGCT exhibited an aver-
age 30% increase in the size of the CD4+ and CD8+ T-cell memory
pool at the time of presentation, we next went on to assess the
effect of treatment on the proportion of na¨ıve and memory T cells.
Interestingly, prospective analysis revealed that the proportion of
T cells within the effector/memory T-cell pool gradually declined
after treatment whereas the na¨ıve T-cell pool increased (Fig. 5C).
In particular, the na¨ıve CD4+ and CD8+ subsets increased signif-
icantly from 38 and 29% to values of 46 and 34% respectively
at 6 months after treatment. Reciprocally, the CD4+ and CD8+
effector memory (TEM) pools fell from 33 and 54% to values of 28
and 46% respectively. Furthermore, we investigated the absolute
numbers of memory T-cell subsets before and after treatment and
found a substantial reduction in both the CD4+ (p = 0.0488) and
CD8+ (p = 0.0059) TEM populations (Fig. 5D). Importantly, there
was no significant change in the number of TNaive cells or the other
memory subsets suggesting an overall loss of TEM cells from the
T-cell pool during follow-up. These data indicate that the inflation
within the memory T-cell pool that was observed at the time of
diagnosis is comprised largely of short-lived effector cells that are
eroded relatively rapidly following treatment.
Discussion
Burnet’s original model of cancer immune surveillance [22] has
now been developed and extended to include the phases of tumor
elimination, equilibrium and escape [23]. Immune-mediated elim-
ination of transformed cells requires the recognition of cancer-
specific epitopes and cancer testis antigens (CTAgs) are one
such class of potential target. Cellular and humoral CTAg-specific
immune responses have been observed in many tumor subtypes
and are suggested to play an important role in the control of dis-
ease progression [24]. In this study, we frequently observed spon-
taneous CTAg-specific T-cell responses ex vivo (by IFN-γ ELISPOT)
in patients with testicular cancer but not in healthy male individ-
uals. In addition, CD8+ T cells specific to known immunogenic
epitopes of MAGE-A family proteins were detectable in testicular
cancer patients (by pMHC-I multimer staining) following short-
term in vitro peptide stimulation cultures.
It is interesting to speculate on the mechanisms that underlie
the priming of immune responses against CTAg proteins in patients
with testicular cancer. CTAg expression has been reported in tes-
ticular germ cell tumors and appears to be largely restricted to
tumors containing seminomatous elements. Indeed, classical semi-
nomas express several MAGE-A family proteins but expression is
absent or rare in NSGCTTs [14, 15, 17, 19, 20, 25]. Interestingly,
this pattern reflects the profile of CTAg-specific immunity that
was observed in the patient cohort, with T-cell immunity being
detected frequently in patients with seminoma and mixed germ
cell tumors. One intriguing observation was that patients with
seminoma and mGCT often developed T-cell responses against
several MAGE-A family proteins whereas patients with NSGCTT
only exhibited immune responses with specificity for MAGE-A3.
Furthermore, these responses to MAGE-A3 were seen only in
patients with NSGCTT who had metastatic disease outside the
testis. MAGE-A3 has been described as a mediator of extracel-
lular matrix protein function which promotes tumor cell migra-
tion [26] and it is therefore possible that expression of MAGE-
A3 is activated during NSGCTT metastasis and that a specific
immune response is subsequently induced at the secondary tumor
site. In addition, it is unlikely that immunogenic CTAg pro-
tein was derived from normal testicular tissue since NY-ESO-1-
specific immune responses were not observed in the present
study even though NY-ESO-1 is expressed strongly by normal tes-
ticular spermatogenic cells [21]. The lack of NY-ESO-1-specific
T-cell responses in our patients could be explained by potential
down regulation of NY-ESO-1 protein during the malignant trans-
formation from pre-malignant GCNIS to clinically overt disease
[21].
Cross-presentation of tumor antigens by dendritic cells at the
tumor site or within tumor-draining lymph nodes is generally con-
sidered the primary mode for priming naive tumor-specific CD8+
T cells [27, 28]. Effective antigen presentation combined with the
high level of CTAg protein that is available in patients with testicu-
lar cancer is likely to lead to the profound level of T-cell expansion
that is observed in this setting. In this regard, it is noteworthy that
C© 2017 The Authors. European Journal of Immunology published by
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Figure 5. The association between the decline of CTAg-specific immunity and the global effector memory (TEM) T-cell pool. (A) Representative
flow cytometry density plots of CCR7 and CD45RA expression on CD4+ and CD8+ T cells used to define TEMRA, TNaive, TEM and TCM memory
subsets in healthy donors and TGCT patients. (B) The proportion of memory CD4+ (left) and CD8+ (right) T-cell subsets in TGCT patients prior
to post-orchidectomy therapy (n = 17) compared with that in healthy donors (n = 12) as measured in (A) are shown. Data are shown as median
+ interquartile range (box) and min. and max. values (whiskers) of n = 17 (TGCT) and n = 12 (healthy) samples. Symbols represent individual
donors. Significance evaluated by Mann–Whitney test. (C, D) The proportion (C) and absolute numbers (D) of CD4+ and CD8+ T cells within defined
memory subsets before therapy (Pre, n = 11) and at Early (<3 months, n = 7) and/or Late (6 months, n = 11) timepoints post treatment were also
measured. Data are shown as median + interquartile range (box) and min. and max. values (whiskers) of the indicated number of donor samples.
Data analyzed by Wilcoxon matched-pairs signed-rank test, *p < 0.05, **p < 0.01, ***p < 0.001.
a large immune infiltrate is seen in virtually every case of semi-
noma [20], which is likely to allow substantial exposure of tumor
antigens to the immune system.
We observed that a large proportion of MAGE-specific CD8+
T cells secreted TNF-α alone following stimulation with CTAg pep-
tides and that this subset was marginally less cytotoxic than cells
which also produced IFN-γ. Previous studies in hepatocellular car-
cinoma [29, 30] and breast cancer [10] patients have shown a
similar phenomenon whereby tumor antigen-specific CD8+ T cells
demonstrated a lack of IFN-γ production. As such, tumor-specific
CD8+ T-cell responses may exhibit unique patterns of functional
competence and at a practical level this indicates that the choice of
IFN-γ ELIPSOT as a functional test is likely to have underestimated
the true frequency of CTAg-specific T cells.
A further interesting aspect of MAGE-specific T-cell immunity
was the detection of both cytotoxic CD8+ and CD4+ T-cell immu-
nity in many patients. Antigen-specific CD4+ T cells are required
for the induction of cross-primed CD8+ T cells responses [31]
and also support the functional activity of secondary immune
responses [32–34]. These data suggest that immunotherapeutic
approaches which seek to induce or expand CTAg-specific CD8+
T-cell immunity should include appropriate epitopes for CD4+
T cells.
Longitudinal analysis in TGCT patients demonstrated a dra-
matic reduction in the number of MAGE-specific T cells within
the blood following treatment. The initial blood samples had been
taken shortly after tumor removal but before adjuvant chemother-
apy. It is possible that adjuvant chemotherapy may trigger apop-
tosis of proliferating tumor-reactive immune cells, including the
loss of MAGE-specific T cells. Alternatively, the decline of CTAg-
specific immunity is likely to reflect the absence of available CTAg
antigen following orchidectomy and as such is similar to the kinet-
ics of decline of adaptive immunity following the clearance of
acute viral and bacterial antigens [35, 36]. In support of this, a
recent publication showed that placental-specific T-cell immune
responses can be established during pregnancy but that these
are short-lived and became undetectable in the periphery after
delivery [37]. It also remains possible that CTAg-specific immu-
nity does in fact persist but becomes unresponsive to antigenic
stimulation due to increased expression of inhibitory checkpoint
receptors such as PD-1 on the cell surface, or an increase in regu-
latory cells such as T-regulatory cells (Tregs) or myeloid-derived
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suppressor cells (MDSCs) in the blood following treatment, as has
been described previously for HPV-specific responses in oropha-
ryngeal patients [38]. Intriguingly, the fall in CTAg-specific immu-
nity correlated with the concurrent decline in memory T-cell sub-
sets and so it is tempting to speculate that MAGE-A-specific T cells
represent a component of a potentially sizeable tumor-specific
effector T-cell repertoire in patients at the time of diagnosis.
Patients with testicular cancer have an excellent clinical out-
come with a cure rate of over 95%. In addition, patients with
seminoma respond very well to therapy even in the setting of
metastatic disease. It is tempting to consider the potential role of
tumor-specific immune responses within this response as the effi-
cacy of chemotherapymay be partially mediated through immuno-
logical mechanisms [39]. The expression of HLA proteins on testic-
ular tumors is low which raises important questions regarding the
potential mechanisms by which a tumor-specific T-cell response
may have some benefit in this disease [40, 41]. The lack of sur-
face HLA expression on tumor cells would mitigate against direct
tumor cell lysis but recognition of local tissue could lead to inflam-
matory responses that may be capable of mediating non-specific
activity against tumor tissue.
Unfortunately, due to the limited availability of fresh autol-
ogous tumor tissue, we were unable to correlate expression of
MAGE antigens with the presence of peripheral MAGE-specific
T-cell populations, or determine if MAGE-specific T cells were
present at the tumor site. However, a previous study demonstrated
the presence of MAGE-A3-specific CD8+ T cells amongst TIL in a
patient with seminoma [25], indicating that CTAg-specific T cells
can infiltrate tumor tissue.
In summary, our data demonstrates that MAGE-specific T-cell
responses frequently develop in many patients with testicular can-
cer, yet these progressively decline as the disease comes under
control. As such patients with testicular cancer represent an excel-
lent opportunity to investigate novel aspects of tumor-specific
immune responses. Moreover, it is possible that strong tumor-
specific immunity plays an important role in mediating the excel-
lent clinical outcome for patients with this condition.
Materials and methods
Study participants
Venous blood samples were obtained from patients prior to, and
after completion of, post-orchidectomy therapy for the treatment
of testicular cancer at the New Queen Elizabeth Hospital, Birm-
ingham, UK (n = 72). All patients had recently undergone radical
orchidectomy to remove the involved testicle. Up to 30 mL hep-
arinized blood was obtained from patients prior to chemotherapy
and at regular intervals following treatment, which coincided with
clinic visits. Up to 50mL of bloodwas donated by healthymale vol-
unteers (n= 22), which were used as controls. Patient and healthy
donor characteristics are shown is Supporting Information Table
1. Written informed patient consent and local ethical committee
approval (South Birmingham research ethics committee LREC ref-
erence 09/H1207/161, study reference RRK3953) were obtained
prior to sample collection. Patients were 18 years or above and
competent to give full informed consent.
Isolation of peripheral blood mononuclear cells
(PBMCs)
PBMCs were isolated from heparinized blood by density gradient
centrifugation over Lymphoprep (Axis-Shield) within 4 h of col-
lection. PBMCs were either assayed fresh (for dextramer analysis)
or cryopreserved in liquid nitrogen (for memory phenotyping and
ELISPOT analysis) in media containing 90% FCS and 10% DMSO.
Memory phenotyping of T cells
PBMCs (5 × 105) were resuspended in 100 μL MACS buffer (PBS,
0.5% BSA, 2 mM EDTA), and surface stained with fluorochrome-
conjugated antibodies on ice for 30 min to identify memory T-cell
subsets (CD3-APCCy7, CD4-PerCPCy5.5, CD8-AmCyan, CCR7-PE
and CD45RA-efluor450). Propidium Iodide (PI) was added prior
to cytometric analysis to exclude non-viable cells. Acquisition was
carried out with an LSRII flow cytometer (BD Biosciences) using
FACSDiva software.
IFN-γ ELISPOT Assay
T-cell responses to CTAgs were measured for each individual
patient in duplicate across all available timepoints using IFN-γ
ELISPOT assays conducted against pools of overlapping 15mer
peptides (pepmixes; JPT Peptide Technologies) spanning the
entire amino acid sequence of each antigen. Previously frozen
PBMCs (5 × 106) from TGCT patients and healthy male donors
were seeded in a 24-well cell culture plate and rested overnight
at 37°C to allow cells to recover from cryopreservation. A Multi-
screen 96-well plate (Millipore) was coated with IFN-γ capture
antibody (Mabtech) at 4°C overnight. PBMCs were harvested
the following day for ELISPOT assay setup and seeded at 2.5–
3.5 × 105 cells/well. For background spot determination, a neg-
ative control containing DMSO solvent only was used for each
patient sample. Test condition wells were incubated with MAGE-
A1, MAGE-A3, MAGE-A4 or NY-ESO-1 pepmixes (1 μg of each
peptide/mL). A CEFT peptide mix (immunogenic peptides derived
from CMV, EBV, Flu and tetanus antigens) was also included as
a positive control. The ELISPOT plates were incubated for 16–
18 h at 37°C and developed as per manufacturer’s instructions
(Mabtech). IFN-γ spots were counted using an AID automated
ELISPOT reader. Each spot is representative of a single reactive
IFN-γ secreting T cell. Mean spot counts for negative control wells
were subtracted from those for the test wells to determine the
frequency of antigen specific T cells. Positive CTAg responses
were defined as the recognition of pepmixes for which the mean
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adjusted counts were 2-fold higher than that of the highest
adjusted spot count observed in our healthy male control cohort.
Intracellular cytokine staining and CD107a
mobilization assay following antigen restimulation
Flow cytometry was used to determine whether responses were
attributable to antigen-specific CD4+ and/or CD8+ T cells. Pro-
duction of effector cytokines IFN-γ and TNF-α, and CD107a mobi-
lization was simultaneously examined following restimulation
with pepmixes. CD107a mobilization to the surface of respond-
ing T cells is a prerequisite for degranulation and was used here
as a marker of cytotoxic potential of CD8+ T cells. Briefly, previ-
ously cryopreserved PBMCs of patients (n= 10) with known CTAg
responses by ELISPOTwere resuspended in RPMI 1640media con-
taining 10% FCS at a concentration of 2 × 106 cells/mL. Cell were
stimulated with pepmixes overnight, then cultured for 10 days in
the presence of 50 U/mL IL-2 from day 3. Cells were then restim-
ulated with pepmixes in the presence of 20 ng/mL CD107a-FITC
antibody. After 1 h, protein transport inhibitors (5.3mMbrefeldin-
A, 1 mMmonensin) were added to each well. Cells were incubated
for a further 4 h, and then surface stainedwith CD3-APC-Cy7, CD4-
PerCP-Cy5.5 and CD8-AmCyan. Cells were washed in PBS, then
fixed and permeabilised with 1% PFA and 0.5% saponin, respec-
tively. Cells were stained intracellularly for the cytokines IFN-γ-
AF700 and TNF-α-PECy7, and then analyzed by flow cytometry.
Unstimulated cells (DMSO only) and CEFT peptide pool served as
negative and positive controls, respectively.
Expansion of antigen-experienced CTAg-specific
CD8+ T cells in short-term T-cell line cultures
Fresh PBMCs were incubated with 10 μg/mL of each peptide
(Table 1) in serum-free RPMI 1640 media for 1 h with gen-
tly agitation. Cells were washed and resuspended in RPMI 1640
media supplemented with 10% human serum, IL-7 (25 ng/mL),
and IL-15 (5 ng/mL) at a concentration of 2 × 106 cells/mL. IL-
2 (50 U/mL) was added to the cultures from day 3. Cells were
cultured for between 10 and 12 days to allow for sufficient T-cell
expansion. Dextramer (pMHC-I multimer; Immudex) staining was
used to identify antigen-specific CD8+ T cells following short-term
culture.
Identification of CTAg-specific CD8+ T cells using
pMHC-I dextramers
T-cell line cultures were stained with pMHC-I dextramers for
20 min at RT in MACS buffer, and washed once prior to surface
staining. Cells were surface stained with CD3-APC-Cy7, CD4-FITC
and CD8-PC5 on ice for 30 min, then washed twice before cyto-
metric analysis. PI was added just prior to cytometric analysis to
exclude non-viable cells. Cells were first gated for lymphocytes
(SSC-A vs. FSC-A), followed by gating for viable CD8+ T cells
(PI−CD3+CD4−CD8+). Dual CD8 and pMHC-I dextramer expres-
sion was then determined from this gated population. A posi-
tive response was reported when the frequency of antigen-specific
dextramer-stained CD8+ T cells was0.05% of total CD8+ T cells,
a threshold described in a number of previous studies [42, 43].
Generation of MAGE-A3-specific T-cell clones
MAGE-A3EVDP dextramer positive cells were enriched using anti-
PE beads and a double MS column isolation procedure under ster-
ile conditions, following the manufacturer’s instructions (Miltenyi
Biotec). The isolated cells were then cloned by limiting dilution
over irradiated (40 Gy) PHA-stimulated allogeneic PBMCs and
peptide-loaded partially-matched lymphoblastic cell lines (LCL)
in RPMI 1640 supplemented with 5% human serum, 5% FCS, IL-2
(100 U/mL), IL-15 (5 ng/mL), and IL-21 (2 ng/mL). For the main-
tenance of the T-cell clones, media containing IL-2 (100 U/mL)
and IL-15 (5 ng/mL) was added twice weekly.
Functional assessment of an EVDP-specific T-cell
clone
Potential MAGE-A3EVDP-specific T-cell clones were initially
screened by staining with dextramer and a single positive clone
was studied further. Effector function was measured by the release
of IFN-γ into culture supernatant following 16 h incubation with
targets cells. Target cells were LCL loaded with relevant peptide
(EVDP), LCL loaded with irrelevant peptide (KVAE) and a cell line
expressing HLA-A1 and MAGE-A3 (HT-29) [44, 45]. Assay con-
trols included T-cell clone only, LCL only and HT-29 only. The cul-
ture supernatant medium was harvested and assayed for IFN-γ by
ELISA (Mabtech) in accordance with the manufacturer’s instruc-
tions. For TCR avidity assays, peptide was titrated from 10−5 to
10−11 M and expressed as a percentage of maximal IFN-γ release.
CD107a mobilization assay was performed as described above.
T cells were stimulated with LCL loaded with either 10 μg/mL
EVDP or KVAE peptides, or with the HT-29 cell line ± EVDP
peptide.
Data handling and statistical analysis
Statistical analysis was performed using GraphPad Prism version
5 (GraphPad Software). To determine differences between two
independent groups, a non-parametric Mann–Whitney test was
performed. A Wilcoxon matched-pairs signed-rank test was used
to compare non-parametric paired data. A linear regression was
performed to assess the relationship between two variables. Spear-
man’s nonparametric test was used to determine correlations. Nor-
mal distribution was assessed using the D’Agostino & Pearson test,
where appropriate. A p value <0.05 was considered statistically
significant.
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